• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Fresenius Medical Care AG

    2/14/25 4:12:46 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care
    Get the next $FMS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Fresenius Medical Care AG

    (Name of Issuer)


    Ordinary Shares, no par value 1.00 euro

    (Title of Class of Securities)


    358029106

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    358029106


    1Names of Reporting Persons

    HARRIS ASSOCIATES L P
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    11,604,675.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    11,717,575.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,717,575.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.9 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    358029106


    1Names of Reporting Persons

    Harris Associates, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    11,604,675.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    11,717,575.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,717,575.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.9 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Fresenius Medical Care AG
    (b)Address of issuer's principal executive offices:

    Else-Kroner-Strasse 1, Bad Homburg, 2M, 2M 61352.
    Item 2. 
    (a)Name of person filing:

    Harris Associates L.P. ("Harris") Harris Associates, Inc. ("General Partner") **Harris Associates, Inc., for itself and as General Partner
    (b)Address or principal business office or, if none, residence:

    111 South Wacker Drive Suite 4600, Chicago, IL 60606
    (c)Citizenship:

    See Item 4 on the cover page(s) hereto.
    (d)Title of class of securities:

    Ordinary Shares, no par value 1.00 euro
    (e)CUSIP No.:

    358029106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    By reason of advisory and other relationships with the person who owns the Shares, Harris may be deemed to be the beneficial owner of the shares specified in Item 9 on the cover page(s) hereto. Harris has been granted the power to vote Shares in circumstances it determines to be appropriate in connection with assisting its advised clients to whom it renders financial advice in the ordinary course of business, by either providing information or advice to the persons having such power, or by exercising the power to vote.
    (b)Percent of class:

    See Item 11 on the cover page(s) hereto.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 on the cover page(s) hereto.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 on the cover page(s) hereto.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 on the cover page(s) hereto.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 on the cover page(s) hereto.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    HARRIS ASSOCIATES L P
     
    Signature:Joseph J. Allessie
    Name/Title:Joseph J. Allessie, General Counsel and Secretary
    Date:02/14/2025
     
    Harris Associates, Inc.
     
    Signature:Joseph J. Allessie
    Name/Title:Joseph J. Allessie, General Counsel and Secretary
    Date:02/14/2025
    Get the next $FMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FMS

    DatePrice TargetRatingAnalyst
    1/20/2026Buy → Neutral
    Goldman
    10/15/2025Neutral → Underperform
    BofA Securities
    9/2/2025Neutral → Sell
    UBS
    12/2/2024Underperform → Neutral
    BofA Securities
    11/6/2024$25.60Buy
    Berenberg
    1/8/2024Equal-Weight → Underweight
    Morgan Stanley
    11/24/2023Reduce → Hold
    HSBC Securities
    11/17/2023Hold → Buy
    Societe Generale
    More analyst ratings

    $FMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

    Strong organic revenue growth1 in 2025 of 8% driven by all operating segmentsDriven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3%Reported operating income grew by 31%, reported net income3 by 82%Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback programDividend of EUR 1.49 (+3%) planned to be proposedFY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwindsBAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains.

    2/24/26 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned

    The second tranche of the share buyback is expected to be executed by May 8, 2026The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, significantly earlier than originally plannedBAD HOMBURG, Germany, Jan. 9, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion. Under the second tranche, the company plans to repurchase its own shares for a t

    1/9/26 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

    Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical OfficerAs part of a planned transition Franklin W. Maddux will retire by year endBAD HOMBURG, Germany, Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer. Mr. Hugh-Jones will succeed Franklin (F

    12/10/25 8:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fresenius Medical downgraded by Goldman

    Goldman downgraded Fresenius Medical from Buy to Neutral

    1/20/26 9:08:47 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical downgraded by BofA Securities

    BofA Securities downgraded Fresenius Medical from Neutral to Underperform

    10/15/25 8:35:43 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical downgraded by UBS

    UBS downgraded Fresenius Medical from Neutral to Sell

    9/2/25 8:32:54 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    SEC Filings

    View All

    SEC Form 6-K filed by Fresenius Medical Care AG

    6-K - Fresenius Medical Care AG (0001333141) (Filer)

    2/24/26 2:56:17 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form IRANNOTICE filed by Fresenius Medical Care AG

    IRANNOTICE - Fresenius Medical Care AG (0001333141) (Filer)

    2/24/26 12:59:30 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 20-F filed by Fresenius Medical Care AG

    20-F - Fresenius Medical Care AG (0001333141) (Filer)

    2/24/26 12:41:18 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Leadership Updates

    Live Leadership Updates

    View All

    Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board

    Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical OfficerAs part of a planned transition Franklin W. Maddux will retire by year endBAD HOMBURG, Germany, Dec. 10, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care, the world's leading provider of products and services for individuals with renal disease, has appointed Charles Hugh-Jones, MD, FRCP (56) as a member of the Management Board, effective January 1, 2026. Mr. Hugh-Jones will serve as Global Chief Medical Officer. Mr. Hugh-Jones will succeed Franklin (F

    12/10/25 8:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement

    Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care EnablementAs part of a planned transition Dr. Katarzyna Mazur-Hofsäß will retire by year endBAD HOMBURG, Germany, Oct. 1, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, has appointed Joseph E. (Joe) Turk (57) as a member of the Management Board, effective January 1, 2026. Mr. Turk will serve as Chief Executive Officer of the global operating segment Care Enablement.

    10/1/25 9:35:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment

    Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician investors in Interwell Health (IWH), accelerating the timeline originally set during the merger of Cricket Health, IWH, and Fresenius Health Partners when it was completed in August 2022Tommy P. O'Connor appointed CEO of Interwell Health and Operating Segment leader of Value-Based Care to enhance benefits of the vertical integration and accelerate value creation in line with the FME Reignite strategyBAD HOMBURG, Germany, Sept. 18, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, to

    9/18/25 3:30:00 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Financials

    Live finance-specific insights

    View All

    Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

    Strong organic revenue growth1 in 2025 of 8% driven by all operating segmentsDriven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in a significant margin step up to 11.3%Reported operating income grew by 31%, reported net income3 by 82%Earnings per share2 (EPS) grew by 44%, supported by the accelerated share buyback programDividend of EUR 1.49 (+3%) planned to be proposedFY 2026 outlook operating income is forecast to remain on a consistent level despite significant additional headwindsBAD HOMBURG, Germany, Feb. 24, 2026 /PRNewswire/ -- "Fresenius Medical Care closed a milestone year marked by outstanding profitability gains.

    2/24/26 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025

    Strong organic revenue growth1 of 10% driven by all operating segmentsPositive U.S. same market treatment growth of 0.1 % in line with expectationsAccelerated operating income2 growth of 28% at constant currency, leading to a step-change in margin expansion to 11.7%Reported operating income grew by 3%, reported net income3 by 29%Net leverage ratio further improved to 2.6x, in parallel to share buyback and Value-Based Care investmentsFY 2025 outlook confirmedBAD HOMBURG, Germany, Nov. 4, 2025 /PRNewswire/ -- "In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income2 growth increased as planned for the third consecutive quarter, underlin

    11/4/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025

    Strong organic revenue growth1 of 7% driven by all operating segmentsStable U.S. same market treatment development driven by accelerating patient inflowFME25+ savings of EUR 58 million contributed to earningsOperating income2 grew by 13% at constant currency, further driving margin expansionStable reported operating income and 20% increase in reported net income3Operating cash flow improved strongly by 75%, net leverage ratio improved to 2.7xFY 2025 outlook confirmedFirst tranche of announced share buyback to be initiated in AugustBAD HOMBURG, Germany, Aug. 5, 2025 /PRNewswire/ -- "In the second quarter of 2025, we further improved our operational performance as strong organic revenue growth

    8/5/25 7:00:00 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    $FMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fresenius Medical Care AG

    SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

    11/14/24 4:08:53 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Fresenius Medical Care AG (Amendment)

    SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)

    2/13/24 1:36:58 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Fresenius Medical Care AG (Amendment)

    SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)

    12/7/23 11:45:52 AM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care